Skip to main content
Delfa

← Trials/Trial dossier/NCT06194552

CompletedPhase 1

A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

A Multiple Ascending Dose, Phase 1, Double-Blind, Study to Investigate the Safety and Pharmacokinetics of NTRX-07 in Healthy Volunteers and Patients With Early Alzheimer's Disease (AD), With an Exploratory Fed-Fasted Assessment

Asset

NTRX-07

Listed sites

2

Recruiting sites

-

Enrollment

32

actual

Study population

Alzheimer’s disease

Key I/E criteria

•prodromal AD•Amyloid biomarker required (CSF)•MMSE 18-27

Primary endpoint

•Treatment-Related Adverse Events

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06194552
Org study IDNTRX-C102

Timeline

Milestones

Study start2022-09-06actual
Primary completion2023-05-31actual
Study completion2023-06-30actual
Study first posted2024-01-08actual
Last update posted2024-01-08actual

Assets

Drug assets

NTRX-07

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age45 Years
Maximum age80 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Participant must be 45 80 years of age inclusive, at the time of signing the informed consent
•Cohorts A-C participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
•Cohort D - AD as characterized by the following clinical, cognitive, and functional criteria.
-Diagnosis of a clinical syndrome of cognitive impairment consistent with prodromal AD per International Working Group (IWG) diagnostic criteria or mild AD per National Institute on Aging - Alzheimer's Association (NIAA-AA) diagnostic criteria
-Self or informant report of memory decline
-Mini-Mental State Examination (MMSE) scores between 18-27 inclusive within the last 4 months
-Objective memory loss by education-adjusted Wechsler Memory Scale Logical Memory II consistent with mild cognitive impairment with Alzheimer's disease (MCI AD) or mild AD
-Absence of significant levels of impairment in other cognitive assessments
•Cohort D - Previous brain imaging study, such as magnetic resonance imaging (MRI) and/or computed tomography (CT), consistent with a diagnosis of probably AD without any other clinically significant co-morbid pathologies within 12 months prior to the Screening Visit. If there has been a significant change in clinical status suggestive of stroke or other possible central neurological disease with onset between the time of the last MRI or CT and the Screening evaluation, the scan should be repeated during Screening procedures if considered appropriate by the Investigator OR Screening cerebrospinal fluid (CSF) results consistent with the presence of amyloid pathology.
•Cohort D - No active depression and a Geriatric Depression Score of <6.
•Cohort D - Absence of other (non-AD) types of dementia.
•Cohort D - Participants previously enrolled in an AD clinical trial involving a disease modifying or symptomatic therapeutic agent may enroll in this study if treatment with the symptomatic therapeutic agent ended more than 6 months before the first dose of NTRX 07-SDD in this study.
•Body weight within 55 110 kg and body mass index (BMI) within the range 18 35 kg/m2 (inclusive)
•Male or Female
•The effects of NTRX 07 on pregnancy, fetal development, and excretion in breast milk is currently unknown. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the subject information sheet, informed consent form (ICF) and in this protocol

Exclusion criteria

•Reported history or presence of clinically significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data. Participants with stable well controlled conditions may be accepted on review with the Investigator and sponsor.
•Reported current or chronic history of clinically significant liver disease. This includes but is not limited to hepatitis virus infections, drug- or alcohol-related liver disease, nonalcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease, α-1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing cholangitis, or any other liver disease considered clinically significant by the investigator.
•Reported hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
•Cohort D - Reside in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision. Participant may reside in such facilities provided continuous direct medical care is not required.
•Cohort D - Unable to provide for self for basic activities of daily living.
•Cohort D - Major structural brain disease by reported history or chart review (eg, ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions, or a single lesion in a critical region eg, thalamus, hippocampus).
•Any other reported history of central nervous system (CNS) trauma (eg, contusion), or infections that affect brain function (eg, human immunodeficiency virus [HIV], syphilis), history of seizures
•Diagnosis of schizophrenia
•Any reported history from patient, family, or on supplied chart review or current suicide risk
•Cohort D - Diagnosis of a dementia-related CNS disease other than AD (eg, Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)
•Reported past or intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing. Specific medications listed in Section Concomittant Therapy may be allowed.
•Reported treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
•Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research.
•Alanine transaminase (ALT) or aspartate transaminase (AST) >1.5 x upper limit of normal (ULN)
•Total bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if total bilirubin is fractionated and direct bilirubin <35%)
•QTcF >450 msec for male participants or >470 msec for female participants
•Positive prestudy drug/alcohol screen
•Positive HIV antibody test
•Clinical laboratory findings outside the normal range and determined by the investigator or medical monitor to be clinically significant.
•Clinically significant abnormalities on screening EEG which may indicate an increased risk of seizure liability.
•Reported sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study
•Reported regular use of known drugs of abuse within the past 3 years.
•Presence of any contraindication to venous blood sampling for pharmacokinetic analyses.
•Positive SARS-CoV-2 test or hepatitis panel (including hepatitis B surface antigen [HBsAg] or hepatitis C virus antibody [anti-HCV]), or a positive HIV antibody screen
•Legal incapacity or limited legal capacity
•Participation in a clinical trial within 30 days prior to product administration.

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
4
Global cognition
3
Amyloid biomarkers
1
Other (unclassified)
1

Global cognition

3 endpoints
Other/protocol endpoint

MOCA Montreal Cognitive Assessment

Time frame:Day 1 and Day 7

Montreal Cognitive Assessment (MoCA)

descriptive

Other/protocol endpoint

MMSE - Mini-Mental Status Exam

Time frame:Day 1 and Day 7

Mini-Mental State Examination (MMSE)

categorical status, descriptive

Other/protocol endpoint

ADAS-COG - Alzheimer's Disease Assessment Scale - Cognitive Scale

Time frame:Day 1 and Day 7

ADAS-Cog

descriptive

Amyloid biomarkers

1 endpoint
Other/protocol endpoint

Plasma levels of neuro-inflammatory biomarkers

Time frame:Day 1 and Day 7

Neurofilament light (NfL)

descriptive

Safety / tolerability / PK

4 endpoints
Primary/protocol endpoint

Number of Participants With Treatment-Related Adverse Events

Time frame:From admission to discharge, up to 2 weeks

event count, event

Secondary/protocol endpoint

Time to Maximum Concentration of NTRX-07 NTRX-07

Time frame:Day 1 and Day 7

time to event, event

Secondary/protocol endpoint

Maximum Concentration of NTRX-07 NTRX-07

Time frame:Day 1 and Day 7

concentration, descriptive

Secondary/protocol endpoint

Area Under the Plasma Concentration Versus Time Curve (AUC) NTRX-07

Time frame:Day 1 and Day 7

concentration, descriptive

Other (unclassified)

1 endpoint
Other/protocol endpoint/low confidence

Plasma levels of high-sensitivity C-reactive protein (CRP)

Time frame:Day 1 and Day 7

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.